膜杰作
Star Staining
分子别名（Synonym）
VSIG3,IgSF11,CXADRL1,Bt-IgSF,CT119
表达区间及表达系统（Source）
Human VSIG3, Fc Tag (VS3-H5258) is expressed from human 293 cells (HEK293). It contains AA Leu 23 - Gly 241 (Accession # Q5DX21-1).
Predicted N-terminus: Leu 23
Request for sequence
蛋白结构（Molecular Characterization）
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 49.7 kDa. The protein migrates as 60-65 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
内毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
纯度（Purity）
>95% as determined by SDS-PAGE.
制剂（Formulation）
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
电泳（SDS-PAGE）
Human VSIG3, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
活性（Bioactivity）-ELISA
Immobilized Human VSIG3, Fc Tag (Cat. No. VS3-H5258) at 5 μg/mL (100 μL/well) can bind Human B7-H5, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. B75-H5258) with a linear range of 0.313-10 μg/mL (Routinely tested).
Protocol
活性（Bioactivity）-SPR
Human B7-H5, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. B75-H5258) Captured on CM5 chip via anti-mouse antibodies surface can bind Human VSIG3, Fc Tag (Cat. No. VS3-H5258) with an affinity constant of 8.87 μM as determined in a SPR assay (Biacore T200) (Routinely tested).
Protocol
Human VSIG3, Fc Tag (Cat. No. VS3-H5258) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human B7-H5, His Tag (Cat. No. B75-H52H0) with an affinity constant of 53.4 μM as determined in a SPR assay (Biacore T200) (Routinely tested).
Protocol
活性（Bioactivity）-BLI
Loaded Human VSIG3, Fc Tag (Cat. No. VS3-H5258) on AHC Biosensor, can bind Human B7-H5, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. B75-H5258) with an affinity constant of 3.7 μM as determined in BLI assay (ForteBio Octet Red96e) (QC tested).
Protocol
Loaded Biotinylated Human B7-H5, Avitag,His Tag (Cat. No. B75-H82E1) on SA Biosensor, can bind Human VSIG3, Fc Tag (Cat. No. VS3-H5258) with an affinity constant of 0.312 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Protocol
Loaded Biotinylated Human B7-H5, Fc,Avitag (Cat. No. B75-H82F3) on SA Biosensor, can bind Human VSIG3, Fc Tag (Cat. No. VS3-H5258) with an affinity constant of 0.617 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Protocol
背景（Background）
VSIG3, also known as IGSF11, BT-IgSF, and CLMP, is a homophilic adhesion molecule that preferentially expressed in the brain. The function of VSIG3 is to stimulate cell growth through homophilic interactions. In clinical, the VSIG3 has been reported to as a novel target for cancer immunotherapy of gastrointestinal and hepatocellular carcinomas. In addition, VSIG-3 is also a ligand of B7 family member VISTA/PD-1H and inhibits human T-cell functions through a novel VSIG-3/VISTA pathway. VSIG-3/VISTA co-inhibitory pathway may provide new strategies for the treatment of human cancers and autoimmune disorders.
